Thyroid Cancer H1 2013

185 views
143 views

Published on

Report reviews key players involved in the therapeutic development for Thyroid Cancer. Thyroid Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
185
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Thyroid Cancer H1 2013

  1. 1. Thyroid Cancer - Pipeline Review, H1 2013 Global Markets Direct’s, 'Thyroid Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Thyroid Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope A snapshot of the global therapeutic scenario for Thyroid Cancer. A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Coverage of products based on various stages of development ranging from discovery till registration stages. A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons to buy Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer. Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. table Of Content introduction global Markets Direct Report Coverage thyroid Cancer Overview therapeutics Development an Overview Of Pipeline Products For Thyroid Cancer thyroid Cancer Therapeutics Under Development By Companies thyroid Cancer Therapeutics Under Investigation By Universities/institutes late Stage Products Thyroid Cancer - Pipeline Review, H1 2013
  2. 2. comparative Analysis mid Clinical Stage Products comparative Analysis early Clinical Stage Products comparative Analysis discovery And Pre-clinical Stage Products comparative Analysis thyroid Cancer Therapeutics – Products Under Development By Companies thyroid Cancer Therapeutics – Products Under Investigation By Universities/institutes companies Involved In Thyroid Cancer Therapeutics Development bristol-myers Squibb Company f. Hoffmann-la Roche Ltd. biogen Idec Inc. sanofi-aventis astrazeneca Plc daiichi Sankyo Company, Ltd merck & Co., Inc. emergent Biosolutions Inc. takeda Pharmaceutical Company Limited plexxikon Inc. reliance Life Sciences Pvt. Ltd. celltrion, Inc. bio-path Holdings, Inc. novartis Ag eisai Co., Ltd. genmab A/s sandoz Inc. exelixis, Inc. celgene Corporation bayer Ag epicept Corporation immunomedics, Inc methylgene Inc bionomics Limited oxigene, Inc. accentia Biopharmaceuticals, Inc. pharmacyclics, Inc. cancer Research Technology Limited memgen, Llc. azaya Therapeutics, Inc. vascular Biogenics Ltd. globeimmune, Inc. biovista Inc. Thyroid Cancer - Pipeline Review, H1 2013
  3. 3. amplimed Corporation curetech Ltd. genelux Corporation trophogen, Inc. thyroid Cancer – Therapeutics Assessment assessment By Monotherapy Products assessment By Route Of Administration assessment By Molecule Type drug Profiles lenvatinib - Drug Profile motesanib Diphosphate - Drug Profile pasireotide - Drug Profile obinutuzumab - Drug Profile sorafenib Tosylate - Drug Profile vandetanib - Drug Profile vandetanib - Drug Profile mocetinostat - Drug Profile ibrutinib - Drug Profile abexinostat Hydrochloride - Drug Profile sar-245409 - Drug Profile panobinostat - Drug Profile dasiprotimut T - Drug Profile docetaxel Liposomal - Drug Profile vemurafenib - Drug Profile cabozantinib - Drug Profile cabozantinib - Drug Profile isf-35 - Drug Profile imexon - Drug Profile vb-111 - Drug Profile bms-936564 - Drug Profile pidilizumab - Drug Profile bp-100-1.02 - Drug Profile trx-201 - Drug Profile autologous Recombinant Idiotypic Vaccine - Drug Profile gi-6207 - Drug Profile epratuzumab - Drug Profile plx-3397 - Drug Profile buparlisib - Drug Profile lithium Carbonate - Drug Profile lenalidomide - Drug Profile di-leu16-il2 Immunocytokine - Drug Profile ofatumumab - Drug Profile fosbretabulin Disodium - Drug Profile Thyroid Cancer - Pipeline Review, H1 2013
  4. 4. rituximab - Drug Profile ocaratuzumab - Drug Profile rituximab Biosimilar - Drug Profile rituximab Biosimilar - Drug Profile etd-5 - Drug Profile abt-199 - Drug Profile rituximab Biosimilar - Drug Profile thyroid Stimulating Hormone Analog - Drug Profile rituximab Biosimilar - Drug Profile plx-4720 - Drug Profile 131i-rituximab - Drug Profile drug Adaptation Program - Drug Profile edc-1 - Drug Profile andrographolide - Drug Profile interferon Alfa-2b Biosimilar - Drug Profile drug For Lung And Thyroid Cancer - Drug Profile glonc-2 - Drug Profile bva-501 - Drug Profile bva-701 - Drug Profile onc-301 - Drug Profile dna Fusion Vaccines - Drug Profile thyroid Cancer Therapeutics – Drug Profile Updates thyroid Cancer Therapeutics – Discontinued Products thyroid Cancer Therapeutics - Dormant Products thyroid Cancer – Product Development Milestones featured News & Press Releases appendix methodology coverage secondary Research primary Research expert Panel Validation contact Us disclaimer ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Thyroid Cancer - Pipeline Review, H1 2013
  5. 5. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Thyroid Cancer - Pipeline Review, H1 2013

×